Ryan J. Watts Denali Therapeutics Inc. (DNLI) insider trading activity

Ryan J. Watts is President and CEO of Denali Therapeutics Inc.. Currently has a direct ownership of 296,833 shares of DNLI, which is worth approximately $5.18 Million. The most recent transaction as insider was on Jan 06, 2026, when has been sold 35,198 shares (Common Stock) at a price of $16.5 per share, resulting in proceeds of $580,767. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 297K

17.29% 3M change

17.29% 12M change

Total Value Held $5.18 Million

Ryan J. Watts Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2026	SELL Open market or private sale	$580,767 $16.5 p/Share	35,198 Reduced 10.6%	296,833 Common Stock
Jan 03 2026	BUY Grant, award, or other acquisition	-	78,960 Added 19.21%	332,031 Common Stock
Jul 09 2025	SELL Open market or private sale	$7,429,230 $15.0 p/Share	495,282 Reduced 66.18%	253,071 Common Stock
Jul 09 2025	BUY Exercise of conversion of derivative security	$1,475,940 $2.98 p/Share	495,282 Added 39.83%	748,353 Common Stock
Jan 07 2025	SELL Open market or private sale	$159,196 $20.81 p/Share	7,650 Reduced 2.93%	253,071 Common Stock
Jan 06 2025	SELL Open market or private sale	$591,758 $20.22 p/Share	29,266 Reduced 10.09%	260,721 Common Stock
Jan 03 2025	BUY Grant, award, or other acquisition	-	54,180 Added 15.74%	289,987 Common Stock

Oct 18 2024	SELL Open market or private sale	$1,107,600 $27.69 p/Share	40,000 Reduced 14.5%	235,807 Common Stock
Oct 18 2024	BUY Exercise of conversion of derivative security	$27,200 $0.68 p/Share	40,000 Added 12.67%	275,807 Common Stock
Aug 20 2024	SELL Open market or private sale	$53,765 $23.79 p/Share	2,260 Reduced 0.95%	235,807 Common Stock
Feb 13 2024	SELL Open market or private sale	$165,793 $17.29 p/Share	9,589 Reduced 3.87%	238,067 Common Stock
Jan 03 2024	BUY Grant, award, or other acquisition	-	89,520 Added 24.7%	272,957 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	82,240 Added 26.18%	231,934 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	$526,373 $7.44 p/Share	70,749 Added 21.35%	260,640 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	62,000 Added 22.49%	213,691 Common Stock

RJW

Ryan J. Watts

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DNLI shares.

Notify only if

Value

Insider Trading

Get notified when an Denali Therapeutics Inc. insider buys or sells DNLI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Denali Therapeutics Inc.

Track Activities on DNLI

Account